<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34425843</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin.</ArticleTitle><Pagination><StartPage>172</StartPage><MedlinePgn>172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-021-01359-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathies that may be accompanied by hypercoagulation and platelet hyperactivation. Recently, a new COVID-19 phenotype has been noted in patients after they have ostensibly recovered from acute COVID-19 symptoms. This new syndrome is commonly termed Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Here we refer to it as Long COVID/PASC. Lingering symptoms persist for as much as 6&#xa0;months (or longer) after acute infection, where COVID-19 survivors complain of recurring fatigue or muscle weakness, being out of breath, sleep difficulties, and anxiety or depression. Given that blood clots can block microcapillaries and thereby inhibit oxygen exchange, we here investigate if the lingering symptoms that individuals with Long COVID/PASC manifest might be due to the presence of persistent circulating plasma microclots that are resistant to fibrinolysis.</AbstractText><AbstractText Label="METHODS">We use techniques including proteomics and fluorescence microscopy to study plasma samples from healthy individuals, individuals with Type 2 Diabetes Mellitus (T2DM), with acute COVID-19, and those with Long COVID/PASC symptoms.</AbstractText><AbstractText Label="RESULTS">We show that plasma samples from Long COVID/PASC still contain large anomalous (amyloid) deposits (microclots). We also show that these microclots in both acute COVID-19 and Long COVID/PASC plasma samples are resistant to fibrinolysis (compared to plasma from controls and T2DM), even after trypsinisation. After a second trypsinization, the persistent pellet deposits (microclots) were solubilized. We detected various inflammatory molecules that are substantially increased in both the supernatant and trapped in the solubilized pellet deposits of acute COVID-19 and Long COVID/PASC, versus the equivalent volume of fully digested fluid of the control samples and T2DM. Of particular interest was a substantial increase in &#x3b1;(2)-antiplasmin (&#x3b1;2AP), various fibrinogen chains, as well as Serum Amyloid A (SAA) that were trapped in the solubilized fibrinolytic-resistant pellet deposits.</AbstractText><AbstractText Label="CONCLUSIONS">Clotting pathologies in both acute COVID-19 infection and in Long COVID/PASC might benefit from following a regime of continued anticlotting therapy to support the fibrinolytic system function.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9108-2384</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa. resiap@sun.ac.za.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlok</LastName><ForeName>Mare</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Analytical Facility: Mass Spectrometry, Stellenbosch University, Tygerberg Campus, Room 6054, Clinical Building, Francie Van Zijl Drive Tygerberg, Cape Town, 7505, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venter</LastName><ForeName>Chantelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezuidenhout</LastName><ForeName>Johannes A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laubscher</LastName><ForeName>Gert Jacobus</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Mediclinic Stellenbosch, Stellenbosch, 7600, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steenkamp</LastName><ForeName>Janami</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PathCare Laboratories, PathCare Business Centre, PathCare Park, Neels Bothma Street, N1 City, Cape Town, 7460, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0001-5838-7963</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa. dbk@liv.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK. dbk@liv.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kemitorvet 200, 2800, Kgs Lyngby, Denmark. dbk@liv.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NNF20CC0035580</GrantID><Agency>novo nordisk foundation center for basic metabolic research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001779">Blood Coagulation Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001779" MajorTopicYN="N">Blood Coagulation Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiplasmin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fibrin(ogen)</Keyword><Keyword MajorTopicYN="N">Long COVID/PASC</Keyword><Keyword MajorTopicYN="N">Microclots</Keyword><Keyword MajorTopicYN="N">Proteomics</Keyword><Keyword MajorTopicYN="N">Serum Amyloid A</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34425843</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pii">10.1186/s12933-021-01359-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46&#x2013;64. doi: 10.1038/s41581-020-00357-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-00357-4</ArticleId><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, et al. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European independent foundation in angiology/vascular medicine. Thromb Haemost. 2020;120(12):1597&#x2013;1628. doi: 10.1055/s-0040-1715798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1715798</ArticleId><ArticleId IdType="pmc">PMC7869052</ArticleId><ArticleId IdType="pubmed">32920811</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Libby P, Ridker PM. COVID-19&#x2014;a vascular disease. Trends Cardiovasc Med. 2021;31(1):1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. MedRxiv. 2021 doi: 10.1101/2021.03.05.21252960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.05.21252960</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Covid-19: the rollercoaster of fibrin(Ogen), D-dimer, Von Willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020;21(14):5168. doi: 10.3390/ijms21145168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21145168</ArticleId><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Heyden EL, Pretorius E. The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol. 2020;11:1221. doi: 10.3389/fimmu.2020.01221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01221</ArticleId><ArticleId IdType="pmc">PMC7271924</ArticleId><ArticleId IdType="pubmed">32574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB. Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol. 2020;19(1):193. doi: 10.1186/s12933-020-01165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01165-7</ArticleId><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C, Bezuidenhout JA, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int J Mol Sci. 2020;21(21):8234. doi: 10.3390/ijms21218234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218234</ArticleId><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts I, Muelas MW, Taylor JM, Davison AS, Xu Y, Grixti JM, Gotts N, Sorokin A, Goodacre R, Kell DB. Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. MedRxiv. 2020 doi: 10.1101/2020.12.09.20246389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.09.20246389</ArticleId><ArticleId IdType="pmc">PMC8686810</ArticleId><ArticleId IdType="pubmed">34928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Renzi S, Landoni G, Zangrillo A, Ciceri F. MicroCLOTS pathophysiology in COVID 19. Korean J Intern Med. 2020 doi: 10.3904/kjim.2020.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2020.336</ArticleId><ArticleId IdType="pmc">PMC10338241</ArticleId><ArticleId IdType="pubmed">32972126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D'Angelo A, De Cobelli F, Rovere-Querini P, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692450</ArticleId><ArticleId IdType="pubmed">32294809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrova L, Kozlovskaya N, Korotchaeva Y, Bobkova I, Kamyshova E, Moiseev S. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): a new variant of thrombotic microangiopathy? Crit Care Resusc. 2020;22(3):284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692496</ArticleId><ArticleId IdType="pubmed">32900338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam LM, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Reilly JP, Pampena MB, Betts MR, Wherry EJ, Song WC, et al. Erythrocytes reveal complement activation in patients with COVID-19. MedRxiv. 2020 doi: 10.1101/2020.05.20.20104398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.20.20104398</ArticleId><ArticleId IdType="pmc">PMC8384475</ArticleId><ArticleId IdType="pubmed">34231390</ArticleId></ArticleIdList></Reference><Reference><Citation>Berzuini A, Bianco C, Paccapelo C, Bertolini F, Gregato G, Cattaneo A, Erba E, Bandera A, Gori A, Lamorte G, et al. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood. 2020;136(6):766&#x2013;768. doi: 10.1182/blood.2020006695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006695</ArticleId><ArticleId IdType="pmc">PMC7414594</ArticleId><ArticleId IdType="pubmed">32559762</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhter N, Ahmad S, Alzahrani FA, Dar SA, Wahid M, Haque S, Bhatia K, Sr, Almalki S, Alharbi RA, Sindi AAA. Impact of COVID-19 on the cerebrovascular system and the prevention of RBC lysis. Eur Rev Med Pharmacol Sci. 2020;24(19):10267&#x2013;10278.</Citation><ArticleIdList><ArticleId IdType="pubmed">33090438</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834&#x2013;847. doi: 10.1002/ajh.25829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25829</ArticleId><ArticleId IdType="pmc">PMC7262337</ArticleId><ArticleId IdType="pubmed">32282949</ArticleId></ArticleIdList></Reference><Reference><Citation>Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi: 10.1111/cob.12365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cob.12365</ArticleId><ArticleId IdType="pmc">PMC7267455</ArticleId><ArticleId IdType="pubmed">32342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates T, Razieh C, Zaccardi F, Davies MJ, Khunti K. Obesity and risk of COVID-19: analysis of UK biobank. Prim Care Diabetes. 2020;14(5):566&#x2013;567. doi: 10.1016/j.pcd.2020.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2020.05.011</ArticleId><ArticleId IdType="pmc">PMC7254007</ArticleId><ArticleId IdType="pubmed">32493608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, Katikireddi SV, Berry C, Pell JP, McMurray JJ, et al. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. Diabetes Metab Syndr. 2020;14(5):1149&#x2013;1151. doi: 10.1016/j.dsx.2020.06.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.06.060</ArticleId><ArticleId IdType="pmc">PMC7326434</ArticleId><ArticleId IdType="pubmed">32668401</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531&#x2013;538. doi: 10.1007/s00392-020-01626-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01626-9</ArticleId><ArticleId IdType="pmc">PMC7087935</ArticleId><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek AE, Raad II, Jabbour E. Cancer and COVID-19. Lancet. 2020;396(10257):1066&#x2013;1067. doi: 10.1016/S0140-6736(20)32070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32070-5</ArticleId><ArticleId IdType="pmc">PMC7544468</ArticleId><ArticleId IdType="pubmed">33038963</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or Post-acute sequelae of COVID-19 (PASC): an overview of 1 biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:1494. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Res Sq. 2021 doi: 10.1101/2021.01.27.21250617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250617</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. As their numbers grow, COVID-19 "Long Haulers" stump experts. JAMA. 2020;324:1381&#x2013;1383. doi: 10.1001/jama.2020.17709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17709</ArticleId><ArticleId IdType="pubmed">32965460</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol. 2020;93:2555&#x2013;2556. doi: 10.1002/jmv.26624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wostyn P. COVID-19 and chronic fatigue syndrome: is the worst yet to come? Med Hypotheses. 2021;146:110469. doi: 10.1016/j.mehy.2020.110469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110469</ArticleId><ArticleId IdType="pmc">PMC7836544</ArticleId><ArticleId IdType="pubmed">33401106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohabbat AB, Mohabbat NML, Wight EC. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):764&#x2013;766. doi: 10.1016/j.mayocpiqo.2020.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocpiqo.2020.08.002</ArticleId><ArticleId IdType="pmc">PMC7661943</ArticleId><ArticleId IdType="pubmed">33204998</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. 2021;18(4):508&#x2013;509. doi: 10.1016/j.hrthm.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7729277</ArticleId><ArticleId IdType="pubmed">33316414</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, Rizk D, Mohammadi N, Breyman E, Nasr L, et al. Post-acute COVID-19 syndrome negatively impacts health and wellbeing despite less severe acute infection. MedRxiv. 2020 doi: 10.1101/2020.11.04.20226126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.04.20226126</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76:396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne) 2020;7:606824. doi: 10.3389/fmed.2020.606824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci. 2011;68(5):785&#x2013;801. doi: 10.1007/s00018-010-0566-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-010-0566-5</ArticleId><ArticleId IdType="pmc">PMC11115092</ArticleId><ArticleId IdType="pubmed">21136135</ArticleId></ArticleIdList></Reference><Reference><Citation>Miszta A, Huskens D, Donkervoort D, Roberts MJM, Wolberg AS, de Laat B. Assessing plasmin generation in health and disease. Int J Mol Sci. 2021;22(5):2758. doi: 10.3390/ijms22052758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052758</ArticleId><ArticleId IdType="pmc">PMC7963172</ArticleId><ArticleId IdType="pubmed">33803235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Oberholzer HM, van der Spuy WJ, Meiring JH. Smoking and coagulation: the sticky fibrin phenomenon. Ultrastruct Pathol. 2010;34(4):236&#x2013;239. doi: 10.3109/01913121003743716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01913121003743716</ArticleId><ArticleId IdType="pubmed">20594045</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumeau C, Awad F, Assrawi E, Cobret L, Duquesnoy P, Giurgea I, Valeyre D, Grateau G, Amselem S, Bernaudin JF, et al. Expression of SAA1, SAA2 and SAA4 genes in human primary monocytes and monocyte-derived macrophages. PLoS ONE. 2019;14(5):e0217005. doi: 10.1371/journal.pone.0217005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217005</ArticleId><ArticleId IdType="pmc">PMC6524798</ArticleId><ArticleId IdType="pubmed">31100086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol. 2017;123:16&#x2013;41. doi: 10.1016/j.pbiomolbio.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2016.08.006</ArticleId><ArticleId IdType="pubmed">27554450</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Thomson GJA, Nunes JM, Engelbrecht AM, Nell TA, de Villiers WJS, de Beer MC, Engelbrecht L, Kell DB, Pretorius E. Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Sci Rep. 2019;9(1):3102. doi: 10.1038/s41598-019-39056-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39056-x</ArticleId><ArticleId IdType="pmc">PMC6395759</ArticleId><ArticleId IdType="pubmed">30816210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Mbotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities. Sci Rep. 2017;7(1):9680. doi: 10.1038/s41598-017-09860-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09860-4</ArticleId><ArticleId IdType="pmc">PMC5574907</ArticleId><ArticleId IdType="pubmed">28851981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol. 2017;16(1):141. doi: 10.1186/s12933-017-0624-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-017-0624-5</ArticleId><ArticleId IdType="pmc">PMC5668975</ArticleId><ArticleId IdType="pubmed">29096623</ArticleId></ArticleIdList></Reference><Reference><Citation>https://assets.thermofisher.com/TFS-Assets/CMD/manuals/Man-4820-4103-UltiMate-3000-RSLCnano-Man48204103-EN.pdf.&#xa0;Accessed 30 June 2021.</Citation></Reference><Reference><Citation>Zinellu A, Paliogiannis P, Carru C, Mangoni AA. Serum amyloid A concentrations, COVID-19 severity and mortality: an updated systematic review and meta-analysis. Int J Infect Dis. 2021;105:668&#x2013;674. doi: 10.1016/j.ijid.2021.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.03.025</ArticleId><ArticleId IdType="pmc">PMC7959678</ArticleId><ArticleId IdType="pubmed">33737133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sack GH., Jr Serum amyloid A&#x2014;a review. Mol Med. 2018;24(1):46. doi: 10.1186/s10020-018-0047-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-018-0047-0</ArticleId><ArticleId IdType="pmc">PMC6117975</ArticleId><ArticleId IdType="pubmed">30165816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Yang JZ, Bai WH, Li ZY, Sun LF, Yan JJ, Zhou CL, Tang BP. Prognostic value of serum amyloid A in patients with COVID-19. Infection. 2020;48(5):715&#x2013;722. doi: 10.1007/s15010-020-01468-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01468-7</ArticleId><ArticleId IdType="pmc">PMC7391472</ArticleId><ArticleId IdType="pubmed">32734556</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q. Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect. 2020;80(6):646&#x2013;655. doi: 10.1016/j.jinf.2020.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.035</ArticleId><ArticleId IdType="pmc">PMC7141628</ArticleId><ArticleId IdType="pubmed">32277967</ArticleId></ArticleIdList></Reference><Reference><Citation>Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18(1):72. doi: 10.1186/s12933-019-0870-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0870-9</ArticleId><ArticleId IdType="pmc">PMC6549308</ArticleId><ArticleId IdType="pubmed">31164120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojouharova M. Classical complement pathway component C1q: purification of human C1q, isolation of C1q collagen-like and globular head fragments and production of recombinant C1q-derivatives. Functional characterization. Methods Mol Biol. 2014;1100:25&#x2013;42. doi: 10.1007/978-1-62703-724-2_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-724-2_3</ArticleId><ArticleId IdType="pubmed">24218248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103&#x2013;2109. doi: 10.1111/jth.14975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14975</ArticleId><ArticleId IdType="pmc">PMC7323352</ArticleId><ArticleId IdType="pubmed">32558075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Tecson KM, McCullough PA. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med. 2020;21(3):315&#x2013;319. doi: 10.31083/j.rcm.2020.03.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2020.03.126</ArticleId><ArticleId IdType="pubmed">33070537</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575&#x2013;e582. doi: 10.1016/S2352-3026(20)30216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15&#x2013;27. doi: 10.1159/000512007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512007</ArticleId><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: a plasmin paradox. J Thromb Haemost. 2020;18(9):2118&#x2013;2122. doi: 10.1111/jth.14960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14960</ArticleId><ArticleId IdType="pmc">PMC7323332</ArticleId><ArticleId IdType="pubmed">32543119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck EG, Denorme F, Holle LA, Middelton EA, Blair AM, de Laat B, Schiffman JD, Yost CC, Rondina MT, Wolberg AS, et al. COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler Thromb Vasc Biol. 2021;41(1):401&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajjan RA, Schroeder V. Role of complement in diabetes. Mol Immunol. 2019;114:270&#x2013;277. doi: 10.1016/j.molimm.2019.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2019.07.031</ArticleId><ArticleId IdType="pubmed">31400630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladikou EE, Sivaloganathan H, Milne KM, Arter WE, Ramasamy R, Saad R, Stoneham SM, Philips B, Eziefula AC, Chevassut T. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond) 2020;20(5):e178&#x2013;e182. doi: 10.7861/clinmed.2020-0346.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0346</ArticleId><ArticleId IdType="pmc">PMC7539718</ArticleId><ArticleId IdType="pubmed">32694169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, L&#xf3;pez JA. Interactions of platelets with subendothelium and endothelium. Microcirculation. 2005;12(3):235&#x2013;246. doi: 10.1080/10739680590925484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10739680590925484</ArticleId><ArticleId IdType="pubmed">15814433</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold KR. Lipid and Lipoprotein Levels in Patients with COVID-19 Infections. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J et al, editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright &#xa9; 2000&#x2013;2021, MDText.com, Inc.; 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33237691</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Chen D, Wu L, He G, Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin Chim Acta. 2020;510:105&#x2013;110. doi: 10.1016/j.cca.2020.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.07.015</ArticleId><ArticleId IdType="pmc">PMC7350883</ArticleId><ArticleId IdType="pubmed">32653486</ArticleId></ArticleIdList></Reference><Reference><Citation>Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost. 2017;43(2):143&#x2013;153. doi: 10.1055/s-0036-1586227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1586227</ArticleId><ArticleId IdType="pubmed">27677178</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307&#x2013;321. doi: 10.1111/j.1365-2141.2005.05444.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2005.05444.x</ArticleId><ArticleId IdType="pubmed">15842654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwaan HC, Lindholm PF. The central role of fibrinolytic response in COVID-19-a hematologist's perspective. Int J Mol Sci. 2021;22(3):1283. doi: 10.3390/ijms22031283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031283</ArticleId><ArticleId IdType="pmc">PMC7919196</ArticleId><ArticleId IdType="pubmed">33525440</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Saleem S, Reed GL. Alpha2-antiplasmin: the devil you don't know in cerebrovascular and cardiovascular disease. Front Cardiovasc Med. 2020;7:608899. doi: 10.3389/fcvm.2020.608899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.608899</ArticleId><ArticleId IdType="pmc">PMC7785519</ArticleId><ArticleId IdType="pubmed">33426005</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed GL, Houng AK, Singh S, Wang D. &#x3b1;2-antiplasmin: new insights and opportunities for ischemic stroke. Semin Thromb Hemost. 2017;43(2):191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592111</ArticleId><ArticleId IdType="pubmed">27472428</ArticleId></ArticleIdList></Reference><Reference><Citation>Seheult JN, Seshadri A, Neal MD. Fibrinolysis shutdown and thrombosis in severe COVID-19. J Am Coll Surg. 2020;231(2):203&#x2013;204. doi: 10.1016/j.jamcollsurg.2020.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2020.05.021</ArticleId><ArticleId IdType="pmc">PMC7290169</ArticleId><ArticleId IdType="pubmed">32593497</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed GL, Matsueda GR, Haber E. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis. Trans Assoc Am Physicians. 1991;104:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">1845147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through &#x3b1;2-antiplasmin cross-linking. Blood. 2011;117(23):6371&#x2013;6374. doi: 10.1182/blood-2011-02-333203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-02-333203</ArticleId><ArticleId IdType="pmc">PMC3448560</ArticleId><ArticleId IdType="pubmed">21471521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen) Integr Biol (Camb) 2015;7(1):24&#x2013;52. doi: 10.1039/c4ib00173g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c4ib00173g</ArticleId><ArticleId IdType="pubmed">25335120</ArticleId></ArticleIdList></Reference><Reference><Citation>de Waal GM, de Villiers WJ, Pretorius E. The link between bacterial inflammagens, leaky gut syndrome and colorectal cancer. Curr Med Chem. 2021 doi: 10.2174/0929867328666210219142737.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867328666210219142737</ArticleId><ArticleId IdType="pubmed">33605849</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius L, Thomson GJA, Adams RCM, Nell TA, Laubscher WA, Pretorius E. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):141. doi: 10.1186/s12933-018-0783-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0783-z</ArticleId><ArticleId IdType="pmc">PMC6214175</ArticleId><ArticleId IdType="pubmed">30388964</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, Levi M, Iba T, Levy JH. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18(9):2138&#x2013;2144. doi: 10.1111/jth.15004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15004</ArticleId><ArticleId IdType="pmc">PMC7404846</ArticleId><ArticleId IdType="pubmed">32881336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>